Lexicon Pharmaceuticals News and Activities

Lexicon Pharmaceuticals is a company listed under the stock ticker LXRX (US).

View the org chart displaying its 25 main executives

Most searched biographies at Lexicon Pharmaceuticals

• Mike Exton, Chief Executive Officer and Director
• Raymond Debbane, Chairman of the Board
• Diane Sullivan, Director

Create your alert
to follow the executive moves at Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Lexicon Pharmaceuticals

• Lexicon Reveals “into the Dark” Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization | Lexicon Pharmaceuticals, Inc.Lexicon Reveals “into the Dark” Awareness Campaign About Vulnerable a
• New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology | Lexicon Pharmaceuticals, Inc.New Analyses
• Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update
• Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2, 2023 | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Host Fourth Quarter 2022 Financial Results Conference Call and Webcast on March 2,
• New Analyses of Sotagliflozin to Be Presented at the American College of Cardiology’s 72nd Annual Scientific Session Together with World Heart Federation’s World Congress of Cardiology | Lexicon Pharmaceuticals, Inc.New Analyses of Sotagliflozin to Be Pre
• Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 41st Annual JP Morgan Healthcare Conference
• Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia | Lexicon Pharmaceuticals, Inc.Lexicon Announces Topline Results from Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia
• Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 34th Annual Piper Sandler Heal
• Lexicon’s LX9211 Shows Significant and Consistent Benefits in the Treatment of Painful Diabetic Neuropathy in Full Results from the Phase 2 RELIEF-DPN-1 Trial Presented at the 16th Annual Pain Therapeutics Summit | Lexicon Pharmaceuticals, Inc.Lexicon’s L
• Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference | Lexicon Pharmaceuticals, Inc.Lexicon Pharmaceuticals to Participate in the 13th Annual Jefferies London Healthcare Conference
• View more press releases Close

Social media about Lexicon Pharmaceuticals

• Lexicon Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Lexicon Pharmaceuticals on LinkedIn, X (Twitter) & YouTube